103189-63-5

Basic information

• Product Name: 3-Amino-butyric acid methyl ester
• Synonyms: 3-Amino-butyric acid methyl ester;Butanoic acid, 3-aMino-, Methyl ester, (3R)-;(R)-3-AMinobutanoic acid Methyl ester;Butanoic acid, 3-aMino-, Methyl ester, (R)-;Methyl (3R)-aMinobutanoate;(R)-Methyl 3-aminobutanoate
• CAS NO: 103189-63-5
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.15
• Mol File: 103189-63-5.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 159.795°C at 760 mmHg
• Flash Point: 33.959°C
• Appearance: /
• Density: 0.988g/cm³
• Vapor Pressure: 2.46mmHg at 25°C
• Refractive Index: 1.427
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• PKA: 8.71±0.10(Predicted)
• CAS DataBase Reference: 3-Amino-butyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-butyric acid methyl ester(103189-63-5)
• EPA Substance Registry System: 3-Amino-butyric acid methyl ester(103189-63-5)

Safety Data

• RIDADR: 3272
• HazardClass: 3
• PackingGroup: Ⅲ
• Hazardous Substances Data: 103189-63-5(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

Uses

(R)?-?Methyl 3-?aminobutanoate is a useful reactant for the stereoselective synthesis of N-?Unprotected β-?Amino Esters.

InChI:InChI=1/C5H11NO2/c1-4(6)3-5(7)8-2/h4H,3,6H2,1-2H3/t4-/m1/s1

Upstream product

• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 
• 3775-72-2 L-3-aminobutyric acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 91366-13-1 (3S)-methyl 3-(p-toluenesulfonyl)butyrate 
• 53562-86-0 (S)-3-hydroxybutyric acid methyl ester 
• 105-45-3 acetoacetic acid methyl ester 
• 623-43-8 crotonic acid methyl ester 
• 678991-47-4 (-)-(3R)-methyl 3-(dibenzylamino)butanoate 
• 134430-97-0 methyl (3R,αR)-3-(N-benzyl-N-α-methylbenzylamino)butanoate 
• 64838-60-4 (3R,1'S)-3-<(1'-phenylethyl)amino>butanoic acid methyl ester 
• 53118-62-0 (R)-3-((S)-1-Phenyl-ethylamino)-butyric acid methyl ester 
• 91366-12-0 methyl (R)-3-(p-toluenesulfonyloxy)butyrate 
• 3976-69-0 Methyl (R)-3-hydroxybutyrate 
• 67-56-1 methanol 

Downstream Products

• 83460-87-1 (S)-3-((S)-3-Benzoylamino-butyrylamino)-butyric acid methyl ester 
• 83509-91-5 (S)-3-[(S)-3-((S)-3-Benzyloxycarbonylamino-butyrylamino)-butyrylamino]-butyric acid methyl ester 
• 83460-92-8 (S)-3-((S)-3-Benzyloxycarbonylamino-butyrylamino)-butyric acid methyl ester 
• 1313618-76-6 C₁₆H₂₅N₃O₅S 
• 1313618-77-7 C₁₆H₂₅N₃O₅S 
• 142035-70-9 methyl (R)-3-(benzyloxycarbonylamino)-butanoate 
• 1425666-73-4 (R)-methyl 3-(ethoxycarbonylamino)butanoate 

Relevant articles and documents

MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE

The present invention relates to a macrocyclic compound as a CDK inhibitor, a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a novel macrocyclic compound represented by a general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, the use thereof as a therapeutic agent, particularly as a CDK inhibitor, and the use thereof in treating cancers, inflammation, viral infections, cardiac hypertrophy or HIV, wherein each substituent of the general formula (I) is the same as that defined in the description.

Synthetic method of (R)-3- n-aminobutanol (by machine translation)

The invention belongs to, the field (R)- 3 - of pharmaceutical and chemical engineering, and particularly relates to a method for. preparing a product (R)- 3 - with good chemical purity, and optical, purity by, a, preparation method of a chiral drug midbody . (by machine translation)

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.